고혈압의 진단 및 치료: 대한고혈압학회 진료지침을 기반으로

키워드

참고문헌 (40)

1. Ettehad D, "Blood pressure lowering for prevention of cardiovascular disease and death : a systematic review and meta-analysis", Lancet, 387, pp.957~967 (2016)
2. Thomopoulos C, "Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials", J Hypertens, 35, pp.2150~2160 (2017)
3. Clark CE, "Association of a difference in systolic blood pressure between arms with vascular disease and mortality : a systematic review and meta-analysis", Lancet, 379, pp.905~914 (2012)
4. Korean Society Hypertension(KSH), "Korea hypertension fact sheet 2018", Clin Hypertens, 24, pp.13~ (2018)
5. Lewington S, "Age-specific relevance of usual blood pressure to vascular mortality : a meta-analysis of individual data for one million adults in 61 prospective studies", Lancet, 360, pp.1903~1913 (2002)
6. Lonn EM, "Blood-pressure lowering in intermediate-risk persons without cardiovascular disease", N Engl J Med, 374, pp.2009~2020 (2016)
7. Zanchetti A, "When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal", J Hypertens, 27, pp.923~934 (2009)
8. Brunström M, "Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels : a systematic review and meta-analysis", JAMA Intern Med, 178, pp.28~36 (2018)
9. Liu L, "The felodipine event reduction(FEVER)study : a randomized long-term placebo-controlled trial in Chinese hypertensive patients", J Hypertens, 23, pp.2157~2172 (2005)
10. ACCORD Study Group, "Effects of intensive blood-pressure control in type 2 diabetes mellitus", N Engl J Med, 362, pp.1575~1585 (2010)
11. SPRINT Research Group, "A randomized trial of intensive versus standard blood-pressure control", N Engl J Med, 373, pp.2103~2116 (2015)
12. Lindholm LH, "The new Japanese society of hypertension guidelines for the management of hypertension(JSH 2014) : a giant undertaking", Hypertens Res, 37, pp.391~392 (2014)
13. Whelton PK, "2017 ACC", AHA, ABC, pp.ACPM, AGS[DOI]
14. Williams B, "2018 ESC", ESH guidelines for the management of arterial hypertension, 2018, pp.39, 3021~3104
15. Williams B, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes : principal results of the conduit artery function evaluation(CAFE)study", Circulation, 113, pp.1213~1225 (2006)
16. Ponikowski P, "2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC", Eur J Heart Fail, 18, pp.891~975 (2016)
17. Thomopoulos C, "Effects of blood-pressure-lowering treatment on outcome incidence in hypertension : 10–Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials", J Hypertens, 35, pp.922~944 (2017)
18. Rosa J, "Role of adding spironolactone and renal denervation in true resistant hypertension : one-year outcomes of randomized PRAGUE-15study", Hypertension, 67, pp.397~403 (2016)
19. Williams B, "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension(PATHWAY-2) : a randomised, double-blind, crossover trial", Lancet, 386, pp.2059~2068 (2015)
20. Leenen FH, "Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial", Hypertension, 48, pp.374~384 (2006)
21. Weber MA, "Cardiovascular events during differing hypertension therapies in patients with diabetes", J Am Coll Cardiol, 56, pp.77~85 (2010)
22. Dahlof B, "Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-scandinavian cardiac outcomes trial-blood pressure lowering arm(ASCOT-BPLA) : a multicenter randomised controlled trial", Lancet, 366, pp.895~906 (2005)
23. Roush GC, "Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone : antihypertensive and metabolic effects", Hypertension, 65, pp.1041~1046 (2015)
24. Brown MJ, "Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure(PATHWAY-3) : a parallel-group, double-blind randomised phase 4 trial", Lancet Diabetes Endocrinol, 4, pp.136~147 (2016)
25. Williamson JD, "Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years : a randomized clinical trial", JAMA, 315, pp.2673~2682 (2016)
26. JATOS Study Group, "Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients(JATOS)", Hypertens Res, 31, pp.2115~2127 (2008)
27. PROGRESS Collaborative Group, "Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack", Lancet, 358, pp.1033~1041 (2001)
28. Odden MC, "Achieved blood pressure and outcomes in the secondary prevention of small subcortical strokes trial", Hypertension, 67, pp.63~69 (2016)
29. Kernan WN, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack : a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2014, pp.45, 2160~2236
30. Zanchetti A, "Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European lacidipine study on atherosclerosis (ELSA), a randomized, double-blind, long-term trial", Circulation, 106, pp.2422~2427 (2002)
31. Zanchetti A, "Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis : principal results of PHYLLIS--a randomized double-blind trial", Stroke, 35, pp.2807~2812 (2004)
32. Hughes TM, "Hypertension and its role in cognitive function : current evidence and challenges for the future", Am J Hypertens, 29, pp.149~157 (2015)
33. Arima H, "Lower target blood pressures are safe and effective for the prevention of recurrent stroke : the PROGRESS trial", J Hypertens, 24, pp.1201~1208 (2006)
34. Godin O, "Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes : the three-city(3C)-dijon magnetic resonance imaging study", Circulation, 123, pp.266~273 (2011)
35. Levi Marpillat N, "Antihypertensive classes, cognitive decline and incidence of dementia : a network meta-analysis", J Hypertens, 31, pp.1073~1082 (2013)
36. Peters R, "Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment(HYVET-COG) : a double-blind, placebo controlled trial", Lancet Neurol, 7, pp.683~689 (2008)
37. Forette F, "Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe(Syst-Eur)trial", Lancet, 352, pp.1347~1351 (1998)
38. Forette F, "The prevention of dementia with antihypertensive treatment : new evidence from the systolic hypertension in Europe(Syst-Eur)study", Arch Intern Med, 162, pp.2046~2052 (2002)
39. Tzourio C, "Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease", Arch Intern Med, 163, pp.1069~1075 (2003)
40. Fagard RH, "Orthostatic hypotension is a more robust predictor of cardiovascular events than nighttime reverse dipping in elderly", Hypertension, 56, pp.56~61 (2010)

관련 논문AI추천